VRTX Stock Recent News
VRTX LATEST HEADLINES
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Charles F. Wagner - Executive VP, COO & CFO Duncan McKechnie - Corporate Participant Reshma Kewalramani - CEO, President & Director Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants David Reed Risinger - Leerink Partners LLC, Research Division Divya Rao - TD Cowen, Research Division Eliana Rachel Merle - UBS Investment Bank, Research Division Evan David Seigerman - BMO Capital Markets Equity Research Geoffrey Christopher Meacham - Citigroup Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C.
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.52 per share, beating the Zacks Consensus Estimate of $4.24 per share. This compares to a loss of $12.83 per share a year ago.
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4.
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
CNBC's Joe Kernen reports on the latest news.